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Adhesion G protein-coupled receptors (aGPCRs)
comprise the second largest yet least studied class
of the GPCR superfamily. aGPCRs are involved
in many developmental processes and immune and
synaptic functions, but the mode of their signal
transduction is unclear. Here, we show that a short
peptide sequence (termed the Stachel sequence)
within the ectodomain of two aGPCRs (GPR126
and GPR133) functions as a tethered agonist. Upon
structural changes within the receptor ectodomain,
this intramolecular agonist is exposed to the seven-
transmembrane helix domain, which triggers G pro-
tein activation. Our studies show high specificity of
a given Stachel sequence for its receptor. Finally,
the function of Gpr126 is abrogated in zebrafish
with a mutated Stachel sequence, and signaling is
restored in hypomorphic gpr126 zebrafish mutants
upon exogenous Stachel peptide application. These
findings illuminate a mode of aGPCR activation and
may prompt the development of specific ligands for
this currently untargeted GPCR family.
INTRODUCTION
Adhesion G protein-coupled receptors (aGPCRs) are among the
largest proteins in nature and consist of a long extracellular
domain (ECD), a seven-transmembrane domain (7TM), and an
intracellular C-terminal tail (ICD) (Figure 1A; Bjarnado´ttir et al.,
2004; McMillan et al., 2002). Another feature of this class is
an autoproteolytic cleavage event that occurs at the GPCR
proteolytic site (GPS), located within the GPCR autoproteoly-
sis-inducing (GAIN) domain, which cleaves aGPCRs into an
N-terminal fragment (NTF) and a C-terminal fragment (CTF)
(Arac¸ et al., 2012; Figure 1A). aGPCRs play essential roles in con-
trolling cell and tissue polarity (Lawrence et al., 2007) and can2018 Cell Reports 9, 2018–2026, December 24, 2014 ª2014 The Autmodulate synaptic functions (O’Sullivan et al., 2012; Su¨dhof,
2001). Although increasing information about aGPCR relevance
is being obtained from mutant animal models, human diseases,
and variant-associated phenotypes, little is known about the
molecular function, activation, and signal transduction of this
receptor class (Langenhan et al., 2013; Liebscher et al., 2013).
The first indirect functional data for G protein coupling by
aGPCRs were obtained in studies of GPR56 by knockdown ex-
periments involving G12/13/p115 RhoGEF pathway components
(Iguchi et al., 2008). An intriguing observation was reported in a
study of gpr126 mutant zebrafish (zf), which exhibit defects in
peripheral myelination (Monk et al., 2009). This phenotype was
reversible through forskolin-induced cyclic AMP (cAMP) eleva-
tion, suggesting Gs-protein coupling. Other studies provided
direct evidence of Gs-protein coupling bymeasuring intracellular
cAMP levels induced by basal activity of the aGPCRs GPR133
(Bohnekamp and Scho¨neberg, 2011) and GPR126 (Mogha
et al., 2013). Furthermore, experiments with chimeric G proteins,
stoichiometric titrations of theGas subunit and receptor, andGas
subunit knockdown experiments (Bohnekamp and Scho¨neberg,
2011) strongly support G protein coupling for GPR133.
Although it is now clear that aGPCRs couple to G proteins,
it remains unclear whether endogenous binding partners
can induce activation of aGPCRs. Interestingly, several studies
have described increased receptor activity when an N-terminal
deletion mutant was expressed (Okajima et al., 2010; Paavola
et al., 2011, 2014; Yang et al., 2011; see Figure 1A). These obser-
vations led to the assumption that the ectodomain functions as
an inverse agonist, although at least two scenarios for aGPCR
activation have been proposed (Liebscher et al., 2013): (1) the
ectodomain contains an inverse agonist that inhibits 7TM
signaling; and (2) ligand binding at the ECD or NTF removal
changes the conformation of an aGPCR and exposes a tethered
agonist (Figures S1A and S1B).
To test these twomodels, we used the human (h) GPR126 and
GPR133 to analyze the contribution of the ECD to receptor basal
activity, because Gs-protein coupling has been experimentally
suggested for these aGPCRs (Bohnekamp and Scho¨neberg,
2011; Gupte et al., 2012; Mogha et al., 2013). Systematichors
Figure 1. Identification of a Putative
Agonistic Region in GPR126 and GPR133
(A) Cartoon of a prototypical aGPCR. The extra-
cellular domain (ECD) contains a signal peptide
(SP) and the GAIN/GPS domain. aGPCRs also
possess a 7TM domain and an intracellular
domain (ICD). Autoproteolysis at the GPS yields
an N-terminal fragment (NTF) and a C-terminal
fragment (CTF). For immunological detection, all
constructs were epitope tagged with an N-termi-
nal HA epitope (yellow square) and a C-terminal
FLAG epitope (green trapezoid).
(B) hGPR126 and hGPR133 constructs (CTF
and DGPS-CTF) lacking the NTF and ECD,
respectively, were generated. Chimeric constructs
were generated by fusing the N terminus of
the human P2Y12 receptor (green line) onto the
GPR126 and GPR133 mutants. The red half-circle
symbolizes the C-terminal portion of the GPS after
its cleavage site. See also Table S1.
(C–E) cAMP levels from COS-7 cells transfected
with WT and mutant GPR126 and GPR133.
(C) P2Y12-CTF mutants have increased basal
activity compared with the WT, and this is abol-
ished in DGPS-CTF mutants.
(D) The constitutive activity of P2Y12-
CTF(GPR126) is increased by deletion of Thr813.
Receptor activity is abolished when the first three
or more aa after the cleavage site are deleted.
(E) Single positions within the C-terminal GPS
sequence were mutated in GPR126 and GPR133
to alanine as shown. See Figures S1C–S1F for
expression studies of all constructs. Data are
shown as means ± SEM of three independent
experiments, each performed in triplicate. Empty
vector (eV) served as the negative control (eV;
cAMP level: 3.68 ± 2.54 nM). Statistics were ob-
tained by two-way ANOVA and Bonferroni post
hoc test: *p < 0.05; **p < 0.01; ***p < 0.001.mutagenesis studies revealed tethered peptide sequences
within themost C-terminal part of the ECD, which specifically ac-
tivates G protein signaling via 7TM interactions in vitro. Finally,
we performed loss-of-function and rescue experiments in
zf gpr126 mutants to confirm the in vivo and evolutionarily
conserved significance of the tethered agonist. Together, our
results define a mechanism of aGPCR activation.
RESULTS
ECD Deletion Activates GPR126 and GPR133
First, we deleted the ECDs of hGPR126 and hGPR133 at
their natural GPS cleavage sites and tested the mutants in
cAMP assays. In these constructs, termed CTF(GPR126) andCell Reports 9, 2018–2026, DeCTF(GPR133), the NTF between the
signal peptide and the GPS cleavage
site was removed, but the ECD part
located C-terminally to the GPS cleavage
site remained attached to the 7TM (CTF
in Figure 1B and Table S1). All mutants
lacking the ECD displayed significantlyincreased basal activities in cAMP assays (Figure 1C), consistent
with results from other NTF-deficient aGPCRs. Both mutants
were poorly detected at the cell surface via hemagglutinin
(HA)-tag staining (Figure S1C). Accordingly, total ELISA and
confocal imaging revealed an absence of the HA tag in
CTF(GPR126) constructs. However, confocal imaging of the
C-terminal FLAG tag showed specific membrane fluorescence
(Figure S1D). We therefore speculate that the HA tags in the
CTFmutant constructs are processed during intracellular protein
maturation, thereby precluding detection. Because the N termini
of rhodopsin-like receptors can improve cell-surface expression
and detection of other GPCRs (Bohnekamp and Scho¨neberg,
2011; Sta¨ubert et al., 2010), we added an HA-tagged P2Y12 N
terminus to the residual ECD of the CTFmutants. This generatedcember 24, 2014 ª2014 The Authors 2019
chimeric P2Y12-CTF(GPR126) and P2Y12-CTF(GPR133) recep-
tors (Figure 1B), which enabled proper plasmamembrane detec-
tion via HA-tag visualization (Figure S1C). As observed for the
CTF constructs, P2Y12-CTF(GPR126) and P2Y12-CTF(GPR133)
displayed high constitutive activity (Figure 1C). These results
demonstrate that deletion of the NTF activates hGPR126 and
hGPR133.
The ECDs of GPR126 and GPR133 Contain Agonistic
Domains
We generated GPR126 and GPR133 mutants in which the entire
ECD, including the entire GPS motif, was deleted or replaced by
the N terminus of P2Y12 (DGPS-CTF; P2Y12-DGPS-CTF; Fig-
ure 1B). None of the constructs displayed constitutive activity
(Figure 1C), although these chimeras were expressed at the
cell surface (Figure S1C). These results argue against the inverse
agonist model of aGPCR activation because constitutive activity
caused by the release of an inverse agonist would not depend on
the presence of the residual GPS motif. These results point to-
ward an activation model that requires the residual GPS motif,
and we hypothesized that the GPS sequence downstream of
the cleavage site contains determinants required for receptor
activation.
To identify this potential tethered agonist, we sequentially
deleted amino acids (aa) C-terminal to the GPS cleavage site
in GPR126. Functional analysis showed that while the most
N-terminal aa (Thr813; Figure 1B) was not essential for receptor
activation (Figure 1D), deletion of the first two, as well as larger
deletions that removed aa following Thr813, abolished basal
receptor activity. This abolishment was not due to expression
changes, since total and cell-surface expression levels were
not significantly different between the constructs (Figure S1E).
To maintain correct aa length C terminal to the cleavage site,
we exchanged several positions with alanine. Again, mutants
with an exchange of position 813 retained constitutive activity,
whereas the exchange of positions 815, 818, and 819 abolished
activity in P2Y12-CTF(GPR126) (Figure 1E), but expression levels
were not affected (Figure S1F). Mutagenesis studies at corre-
sponding positions in P2Y12-CTF(GPR133) revealed almost
identical results (Figures 1E and S1F). These experiments sup-
port the existence of a defined agonistic region C-terminal to
the GPS.
A Tethered Peptide Activates GPR126
To demonstrate that the aa sequence C-terminal to the GPS
cleavage site has agonistic properties, we tested peptides
derived from this domain on P2Y12-DGPS-CTF(GPR126). Excit-
ingly, systematic truncation of the peptide’s C terminus revealed
several agonistic peptides (Figure 2A). The most efficient pep-
tide, p16 (16 aa long), was used for further structure-function
studies. N-terminal deletion of the first two aa abolished the
agonistic abilities of p16 (p16-1 and p16-2; Figure 2A). This
does not contradict the results of Figures 1D and 1E, because
in the original CTF mutants, the first aa were replaced by the
P2Y12 N terminus or by alanine. Thus, these changes are toler-
ated, whereas the deletions in p16 are not. N-terminal extension
beyond the cleavage site by one (p16+1) or two to four (p16+2 to
p16+4) aa showed reduced or no agonistic activity of p16,2020 Cell Reports 9, 2018–2026, December 24, 2014 ª2014 The Autrespectively (Figure 2A). This indicates that noncleaved aa
upstream of Thr813 are not part of the agonistic structure.
In concentration-response curves, p16 displayed low potency
(EC50 > 400 mM) on both P2Y12-DGPS-CTF(GPR126) and wild-
type (WT) GPR126 (Figure 2B), which can be explained by the
natural 1:1 stoichiometry of the covalently bound agonist in
its natural conformation. The higher cell-surface expression
of WT GPR126 compared with P2Y12-DGPS-CTF(GPR126; Fig-
ure S1C) explains the increased efficacy of p16 on WT GPR126
activation. Time-course analyses of cAMP accumulation (Fig-
ure S2A) and GTPgS binding assays (Figure S2B) in response
to p16 supported p16-induced G protein coupling in GPR126-
transfected cells. Note that eV-transfected cells showed residual
cAMP accumulation (Figure 2C) and GTPgS binding, indicating
endogenous expression of GPR126 in COS-7 cells. This was
confirmed by RT-PCR (Figure S2C), cAMP assays (Figure 2C),
and kinetic dynamic mass redistribution (DMR) measure-
ments (Epic; Corning Life Sciences) with small interfering RNA
(siRNA)-mediated knockdown of the endogenous GPR126
(Figures S2D and S2E).
The endogenous expression of GPR126 and the high sensi-
tivity of the DMR technology enabled us to test p16 apart from
heterologous overexpression systems. As shown in Figure 2D,
p16 induced concentration-dependent cellular responses very
similar to those found with isoprenaline and b-adrenergic recep-
tor endogenously expressed in COS-7 cells. Mutation of position
6 (Leu6Ala) in p16 abolished the response (Figure 2D), confirming
specificity. To identify functionally relevant positions in the
peptide, we performed a systematic alanine scan (Figure 2E).
As expected from our receptor mutagenesis data (Figures 1D
and 1E), the more N-terminal aa (positions +2 to +7) were
required for agonistic activity, whereas positions +8, +10, +12,
and +14 to +16 could be replaced with Ala and still show
agonistic properties. These data are in line with a high evolu-
tionary conservation of the N-terminal portion of this peptide
sequence (Figure S2F). Interestingly, the peptide p16 Gly4Ala
blocked p16-induced GPR126 activation at double concentra-
tion (Figure 2F), indicating that p16 Gly4Ala can compete with
the p16 binding site. Together, these data support the notion
that the tethered peptide p16 activates GPR126.
A Tethered Peptide Activates GPR133
To determine whether activation by a tethered peptide is com-
mon for aGPCRs, we performed similar studies with GPR133.
The P2Y12-DGPS-CTF(GPR133) could be activated by a peptide
derived from the 13 aa (p13) downstream of the putative cleav-
age site (Figure 3A). Concentration-response measurements of
p13 revealed specific activity on P2Y12-DGPS-CTF(GPR133)
and WT receptor (EC50 > 400 mM; Figure 3B). The derived pep-
tides were highly specific for the aGPCR from which they origi-
nated: GPR133 p13 did not activate GPR126, and GPR126
p16 did not activate GPR133 (Figure 3C). Because the impor-
tance of GPS cleavage for aGPCR expression and activity has
been the subject of controversy (Liebscher et al., 2013), we
tested two cleavage-deficient mutants: GPR126T841A (Morigu-
chi et al., 2004) and GPR133H540R (Bohnekamp and Scho¨ne-
berg, 2011). Bothmutants were expressed and activated by their
respective peptides (Figures S2G–S2I), indicating that cleavagehors
Figure 2. GPR126 Agonistic Peptides Are Derived from the C-Terminal Part of the GPS
(A) Application of 1 mM peptides of different lengths derived from the C-terminal part of the GPS, beginning at the cleavage site of GPR126, revealed agonistic
properties as measured by cAMP accumulation. The highest agonistic efficacy was detected for a peptide containing 16 aa (p16). Negative controls: eV and
GPR126-P2Y12-DGPS-CTF mutant. Basal cAMP levels were 3.8 ± 1.6 nM.
(B) Different p16 concentrations were tested on WT P2Y12, WT GPR126, and P2Y12-DGPS-CTF. Inset: the concentration-response curve of p16 at WT GPR126
revealed an EC50 > 400 mM. Basal eV levels were 3.2 ± 0.7 nM.
(C) COS-7 cells endogenously express low levels of GPR126 (see Figure S2C). Endogenous and transfected GPR126 were knocked down with primate GPR126-
specific siRNA as shown by abolished cAMP formation (x-fold over eV; basal cAMP: 5.5 ± 2.2 nM). This was confirmed by a DMR assay (Epic biosensor
measurements; Figure S2D) and reduced cell-surface ELISA (see Figure S2E).
(D) The specificity of p16 was confirmed on endogenous GPR126. Mutation of position 6 (Leu6Ala) abolished the response of p16 in Epic measurements, as
indicated by a picometer (pm) shift of the resonant wavelength caused by DMR within the cell.
(E) A systematic alanine scan within the p16 peptide showed that the six aa downstream of Thr813 are required for receptor activation. Basal cAMP levels were
3.8 ± 1.6 nM.
(F) p16 Gly4Ala (1 mM) blocked activation of GPR126 by p16 (500 mM). Basal cAMP levels were 18.7 ± 9.4 nM. Data are shown as means ± SEM of three
independent experiments, each performed in triplicate. Statistics were obtained by two-way ANOVA and Bonferroni post hoc test: *p < 0.05; **p < 0.01;
***p < 0.001.at the GPS is not required for aGPCR activation by the tethered
agonistic peptides. These data demonstrate that the tethered
peptide p13 activates GPR133. Together with our analysis of
GPR126, these studies suggest that tethered peptide activation
is a common signaling modality for the aGPCR class.
Tethered Peptide Activation of Gpr126 In Vivo
We next sought to test the in vivo relevance of aGPCR tethered
peptide activation. For these studies, we used zf because previ-
ous mutant analyses demonstrated that Gpr126 is essential for
Schwann cell myelination and ear development and that theseCell Rephysiological functions require cAMP elevation (Geng et al.,
2013; Monk et al., 2009). Although several zf gpr126 mutant
alleles have been recovered in genetic screens (Pogoda et al.,
2006), none specifically affect the tethered agonist sequence.
Therefore, we utilized transcription-activator-like effector nucle-
ases (TALENs) to target this region (Figures S3A and S3B).
We isolated a mutant, gpr126stl215, which lacks only two codons
(Gly831-Ile832) within the tethered agonist sequence (Figures 4A,
4B, and S3C). The gpr126stl215 mutants were grossly normal
compared with WT animals (Figure S3D), but developed swollen
ears (Figure 4C), failed to express myelin basic protein (mbp, aports 9, 2018–2026, December 24, 2014 ª2014 The Authors 2021
Figure 3. Tethered Agonistic Peptides Are
Receptor Specific
(A) Application of 1 mM peptides of different
lengths derived from the C-terminal part of the
GPS, beginning at the cleavage site of GPR133,
revealed agonistic properties as measured by
cAMP accumulation. The highest agonistic effi-
cacy was detected for a peptide containing 13
aa (p13). Negative controls: eV and GPR126-
P2Y12-DGPS-CTF mutant. Basal cAMP levels
were 5.2 ± 2.0 nM.
(B) The concentration-response curve of the p13
peptide revealed an EC50 > 400 mM. Basal eV
levels were 2.9 ± 0.2 nM.
(C) Specificity of the p16 (GPR126) and the p13
(GPR133) peptides were verified using WT P2Y12,
WT GPR126, and WT GPR133 as controls. p16
peptide activated WT GPR126 and P2Y12-DGPS-
CTF(GPR126), whereas it exhibited unspecific
activity in control receptors due to endogenous
expression of GPR126 inCOS-7 cells (Figure S2C).
Thep13 peptide specifically activatedWTGPR133
and P2Y12-DGPS-CTF(GPR133). Basal cAMP
levels were 3.0 ± 0.8 nM. Data are shown asmeans
± SEM of three independent experiments, each
performed in triplicate. Statistics were obtained
by two-way ANOVA and Bonferroni post hoc test:
*p < 0.05; **p < 0.01; ***p < 0.001.
See also Table S1.marker of mature Schwann cells) along the posterior lateral line
nerve (PLLn) (Figures 4D and 4E), and did not myelinate periph-
eral axons (Figures S3E–S3H). These defects completely pheno-
copy the previously published gpr126st49 mutant, which has an
early stop codon in the GAIN domain upstream of the GPS motif
(Figure 4B; Monk et al., 2009). Importantly, the Gly831-Ile832
deletion introduced by the gpr126stl215 mutation did not alter
the cell-surface expression of the receptor (Figures S4A and
S4B). Therefore, we conclude that the phenotypes observed in
gpr126stl215 mutants are caused by loss of a functional tethered
agonist.
Finally, we tested whether p16 serves as an agonist for endog-
enous Gpr126 in vivo, using zf PLLn mbp expression as an
assay. The gpr126st63 allele contains a point mutation in the first
extracellular loop of the 7TM that converts a conserved cysteine
residue to tyrosine (C917Y; Figure 4B; Monk et al., 2009). This
mutant receptor shows reduced cell-surface expression
compared with the WT (60% of WT levels; Figure S4A) and a
concomitant reduction in basal activity (Figure S4B). In vivo,
mbp expressed is reduced, but not absent, along the PLLn
(Pogoda et al., 2006). In contrast,mbp expression is completely2022 Cell Reports 9, 2018–2026, December 24, 2014 ª2014 The Authorsabsent along the PLLn of the strong loss-
of-function gpr126st49 and gpr126stl215
mutants (Figures 4D and 4E). Therefore,
we predicted that the gpr126st63 allele
produces a hypomorphic Gpr126 pro-
tein with reduced signaling capability.
Accordingly, our ultrastructural analysis
revealed that gpr126st63 mutants can
myelinate axons in the PLLn, althoughfewer axons are myelinated than in the WT (Figures S4C and
S4D) (S.C.P. and K.R.M., unpublished data).
Because we can infer that gpr126st63 mutants possess a
partially functional 7TM, we hypothesized that exogenous addi-
tion of p16 could increase the signaling of endogenous hypomor-
phic Gpr126. This assay is feasible given that small molecules,
including peptides, can freely diffuse into the developing larva
in the presence of a carrier (Morash et al., 2011), and because
the functionally important positions in p16 are almost 100%
identical between Danio rerio and Homo sapiens (Figure S2F).
Indeed, p16 was able to activate WT zf Gpr126 in in vitro
cAMP assays (Figure S4B). Therefore, we treated gpr126st63mu-
tants with 100 mM p16 in DMSO from 50–55 hr postfertilization,
which constitutes a temporal window in which cAMP elevation
by forskolin administration can rescue myelination in gpr126st49
mutants (Glenn and Talbot, 2013; Monk et al., 2009). We then
qualitatively scored mbp expression in the PLLn (Figure 4A).
As a negative control, we treated siblings with DMSO and
observed normal PLLn mbp expression in the WT (gpr126+/+ or
gpr126st63/+) and reduced or absent mbp in hypomorphic
gpr126st63/st63 mutants (Figures 4F–4K). Treatment with
100 mM p16 caused no significant change in WT larvae, but
significantly rescued mbp expression in gpr126st63/st63 hypo-
morphs (0% ‘‘strong’’ or ‘‘some’’ in gpr126st63/st63 + DMSO
versus 44% ‘‘strong’’ or ‘‘some’’ in gpr126st63/st63 + p16; Figures
4H, 4J, and 4K). To test whether this effect is specific to Gpr126
signaling, we also assayed strong loss-of-function gpr126st49
mutants, which presumably do not express a 7TM (Patra
et al., 2013). Exogenous treatment of gpr126st49 mutants with
100 mM p16 did not rescue mbp expression in the PLLn (Fig-
ure 4K), indicating that p16 signals through the 7TM. Together,
these loss- and gain-of-function experiments in zf demonstrate
the in vivo relevance of tethered peptide activation of aGPCRs.
DISCUSSION
We define a common intramolecular agonistic domain for the
aGPCRs GPR126 and GPR133 that comprises a sequence be-
tween the GPS cleavage site and TM1. Because of its activating
nature and its position at the very C terminus of the ECD, we refer
to this agonistic sequence as the ‘‘Stachel sequence’’ (Stachel
is the German word for stinger). Our analysis of gpr126stl215 sug-
gests that Stachel-mediated activation of Gpr126 is essential for
Schwann cell myelination in zf (Figures 4C–4E and S3E–S3G);
however, the in vivo mechanisms that unmask this tethered
agonistic domain are unknown. GAIN domain crystal structures
revealed that the Stachel sequence lies buried between two b
sheets (Arac¸ et al., 2012). We and others have shown that
CTF-only truncation mutant aGPCRs possess increased basal
activity (Figures 1C–1E; Okajima et al., 2010; Paavola et al.,
2011, 2014; Yang et al., 2011). In all of these studies, the critical
GAIN domain b sheets were deleted along with the rest of the
NTF, presumably exposing the Stachel sequence. Therefore,
structural changes in vivo due to extracellular molecules inter-
acting with the ECD (Langenhan et al., 2013; Liebscher et al.,
2013) or even mechanical removal of the NTF may expose the
Stachel sequence to activate the 7TM. The low affinity of the
Stachel sequence to the 7TM suggests a fast on/off ligand-re-
ceptor interaction and supports activation bymechanical signals
(Karpus et al., 2013).
Peptide agonists usually bind to their cognate receptor in a
sequential two-step mechanism (Monteclaro and Charo, 1996).
The first step requires high-affinity interactions with extracellular
loop regions, whereas the second step is mediated by low-affin-
ity interactions with the helix bundle, promoting receptor activa-
tion. Based on our findings, the first step is not required for
aGPCRs, because the activating peptide is part of the receptor’s
own ECD and therefore covalently bound to the 7TM. In the
second step of our model of aGPCR activation, the Stachel
sequence is predicted to interact with extracellular loops and
upper helix bundles as in other peptide/peptide-GPCR pairs
(Thompson et al., 2012), which requires a low affinity. This model
is also consistent with protease-activated receptors in which
thrombin cleaves the receptor’s N terminus and exposes an acti-
vating tethered agonist (Vu et al., 1991).
Large ECDs are not unique to the aGPCR family. The ectodo-
mains of glycoprotein hormone receptors (the rhodopsin-like
GPCR class) are also composed of several hundred aa forming
leucine-rich repeat domains. In glycoprotein hormone receptors,Cell Rea conserved module termed the hinge region (Sangkuhl et al.,
2002) connects the ECD to the 7TM in a manner similar to that
observed for the GPS domain in aGPCRs. Although the inter-
spaced hinge region does not share the predicted 3D structural
identity with the GPS motif, both the hinge region and the GPS
motif possess multiple disulfide bonds that form at least two
loops of the polypeptide chain (Arac¸ et al., 2012). Interestingly,
hinge-region mutations of glycoprotein hormone receptors can
activate these rhodopsin-like GPCRs, suggesting an ‘‘intramo-
lecular agonistic unit’’ (Krause et al., 2012). Similarly, mutations
in Cys775, Cys794, Cys807, and Cys809 of GPR126, which normally
form disulfide bridges in theGAIN domain, displayed constitutive
activity in cAMP assays (Figures S4E and S4F). These data pro-
vide further evidence that structural changes in the GPS region
promote activation via the Stachel sequence.
Our results are compatible with an activation scenario
of aGPCRs in which an intramolecular agonistic domain (the
Stachel sequence) is unmasked upon structural changes of the
ECD, which subsequently triggers 7TM-mediated activation of
G protein-signaling cascades (Figures S1B [cis signaling] and
S4G). Recent evidence indicates that the ECD of GPR126 and
other aGPCRs can mediate biological functions independently
of the 7TM (trans signaling) (Patra et al., 2013; Pro¨mel et al.,
2012). Our discovery may facilitate attempts to distinguish be-
tween trans- and cis-dependent functions; for example, pheno-
typic perturbations inmodel organisms through peptide agonists
could be attributed to cis signaling of the receptor (e.g., Figures
4F–4K). Our study defines a signaling modality for aGPCRs and
lays the foundation for rational ligand design to promote a
deeper understanding of the physiology and therapeutic useful-
ness of this emerging class of GPCRs.
EXPERIMENTAL PROCEDURES
aGPCR Constructs and Functional Assays
Epitope-tagged, full-length human aGPCR sequences were inserted into
pcDps, and mutant aGPCRs were generated by PCR (Table S1). For func-
tional assays, transfected COS-7 cells were split into 48-well plates and
cAMP concentrations were determined with the Alpha Screen cAMP assay
kit (PerkinElmer Life Sciences) according to the manufacturer’s protocol.
To measure label-free receptor activation, a DMR assay (Epic biosensor
measurements; Corning Life Sciences) with COS-7 cells endogenously ex-
pressing GPR126 was performed as previously described (Schro¨der et al.,
2010). To estimate cell-surface and total expression of receptors carrying
N-terminal HA and C-terminal FLAG tags, ELISA was used (Scho¨neberg
et al., 1998). Assay data were analyzed with GraphPad Prism version 6.0
for Windows (GraphPad Software) and statistical details are given in each
figure legend.
Peptide Synthesis
Solid-phase peptide synthesis of the peptides was performed on an auto-
mated peptide synthesizer (MultiPep; Intavis AG) using standard Fmoc
chemistry.
Zebrafish Studies
Adult zebrafish were maintained in the Washington University Zebrafish
Consortium facility in accordance with institutional animal protocols (http://
zebrafish.wustl.edu/husbandry.htm). Embryos were collected from heterozy-
gous gpr126 mutant adults, and mutant larvae were compared with WT sib-
lings for all assays. See the Supplemental Experimental Procedures for details
on TALEN mutagenesis, in situ hybridization, transmission electron micro-
scopy, and peptide treatment.ports 9, 2018–2026, December 24, 2014 ª2014 The Authors 2023
Figure 4. Tethered Agonistic Peptides Function In Vivo
(A) Sequences of WT and stl215 alleles. stl215 is characterized by a 6 bp in-frame deletion, which results in the removal of aa Gly831 and Ile832. The BtsCI
restriction enzyme site targeted by the TALEN is underlined.
(B) Schematic representation of Gpr126 showing the stl215 allele compared with st49 and st63 alleles.
(C) Dorsal view of 4 days postfertilization (dpf) larvae. Arrowheads indicate normal ear morphology in the gpr126+/+ larva (WT) and swollen ears in the
gpr126stl215/stl215 larva (stl215).
(D) Lateral view of whole-mount in situ hybridization (WISH) of zf larvae at 4 dpf. The posterior lateral line nerve (PLLn) is marked with an arrow;mbp expression in
the CNS is indicated with an arrowhead. mbp expression can be observed in the CNS, but not in the PLLn of gpr126stl215/215 mutant larvae (st215).
(E) Quantificationof the swollen ear phenotypeandPLLnmbp expressionout of the total number of larvae scoredper genotype (WT=gpr126+/+andgpr126stl215/+).
(legend continued on next page)
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Additional details regarding the methods used in this work are available in
the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.11.036.
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